Showing results (261-270 of 319) with videos related to
Sort By:
Pageof 32
Cancer Research and Treatment|February 6, 2018
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST TrialChoong-Kun Lee, Minkyu Jung, Hyo Song Kim, et al.Cancer Research|March 22, 2012
AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancerYon Hui Kim, Han Liang, Xiuping Liu, et al.The Lancet. Oncology|December 3, 2014
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trialSung Hoon Noh, Sook Ryun Park, Han-Kwang Yang, et al.Nature Communications|October 12, 2022
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancerChoong-Kun Lee, Sun Young Rha, Hyo Song Kim, et al.BMC Cancer|November 17, 2018
Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapySeung-Hoon Beom, Yoon Young Choi, Song-Ee Baek, et al.British Journal of Cancer|June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyTaroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.Lancet (London, England)|October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.Pageof 32